Researchers reveal reason for olfactory dysfunction in initial stage of Alzheimer's disease

A research team led by DGIST Professor Moon Cheil at the Department of Brain and Cognitive Sciences has identified the reason why the patients with the early stage of Alzheimer's fail to smell.

The research team of Professor Moon Cheil conducted a joint research with the research teams led by Professor Suh Yoo-Hun and Chang Keun-A at Gachon Medical School and they have revealed the mechanism of the relationship between the initial progression of Alzheimer's and the olfactory dysfunction.

Alzheimer's disease (AD) is the most representative degenerative brain disease, accounting for 60 to 80% of all dementia cases. The greatest known risk factor is aging as the majority of people with Alzheimer's are 65 and older. In particular, Alzheimer's disease is becoming a serious social problem in Korea as the number of patients with degenerative brain disease increases as the country is entering an aging society at an unprecedented rate.

Currently, there is no underlying cure for dementia, but early detection of dementia may be able to ameliorate or delay the onset of symptoms. Some of the drugs available in the market are also focused on relief or delay of symptoms rather than direct treatment itself of dementia. Since those treatments are effective only when administered in a timely manner, it is important to diagnose Alzheimer's in the early stage.

In the initial stage of Alzheimer's disease, it is known that a toxic protein called 'beta- amyloid' is abnormally overexpressed and accumulates in the brain and adversely affect neuronal cells.

The sooner Alzheimer's is diagnosed, the greater the chance for perfect cure. Hence, there has been a worldwide effort underway to find inexpensive, but accurate way to detect early-stage AD. In particular, recent studies have reported the association between Alzheimer's and olfactory deterioration by suggesting that the initial symptoms of Alzheimer's can be simply checked in the olfactory test using peanut butter. However, the specific mechanism was not clearly revealed.

Professor Moon's research team paid attention to the olfactory dysfunction in the early stage of Alzheimer's dementia and studied not only the brain, the central nervous system, but also the peripheral nervous system, the olfactory nervous system. The researchers carried out a behavioral experiment using an animal model with Alzheimer's and have confirmed that the initial olfactory dysfunction, which is found in Alzheimer's disease, is progressed in the six-month-old, earlier than in the fourteen-month-old when brain cognitive dysfunction occurs.

The AD brain has been histologically characterized by the presence of neuritic plaques - inflammatory lesion of nerves - and tangles of neuro-fibril, which are composed of protein aggregates of amyloid β (Aβ, beta-amyloid) and tau; the Aβ is known to be expressed only in the central nervous system. However, the research team also detected direct expression of Aβ in the olfactory epithelium, a peripheral nervous system, itself. Furthermore, it has also been proved that Aβ has a fatal effect on the olfactory nerve cell in olfactory epithelium and directly induces the failure of olfactory function.

Professor Mon Cheil said "We have discovered an important clue to predict the onset of Alzheimer's disease in the early stage by identifying the mechanism of beta-amyloid expression in the initial stage of Alzheimer's that was unknown until now. We will carry out the follow-up researches that can be used for the development of early detection of dementia, dementia treatment technology, and more."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Microglial cells may hold key to Alzheimer's plaque removal